OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Zhen on Future Research Efforts in Neuroendocrine Carcinomas

August 18th 2022

David Zhen, MD, discusses future research efforts in poorly differentiated small cell neuroendocrine carcinomas.

Dr. Goldkorn on the Methods Used to Predict Chemotherapy Benefit in Bladder Cancer

August 18th 2022

Amir Goldkorn, MD, discusses the methods utilized to predict chemotherapy benefit in bladder cancer.

Dr. Bhatt on the Longitudinal Effects of Chronic Diseases in Childhood Cancer Survivors

August 18th 2022

Neel S. Bhatt, MBBS, MPH, discusses the longitudinal effects of chronic diseases in childhood cancer survivors.

Women in Oncology: How Early Treatments Paved the Way for Future Advances

August 18th 2022

Selina M. Luger, MD, FRCPC; Gail J. Roboz, MD; and Wendy Stock, MD, discuss the challenges that accompanied the lack of progress in leukemia treatment when they began their fellowships and express their excitement about encouraging developments that have since emerged in the arena.

Dr. Ip on Next-Generation Sequencing in Myeloid Neoplasms

August 17th 2022

Andrew Ip, MD, discusses the use of targeted next-generation sequencing in detecting chromosomal structural abnormalities in patients with myeloid neoplasms.

Dr. Usmani on the Rapidly Evolving Landscape in Multiple Myeloma

August 17th 2022

Saad Z. Usmani, MD, MBA, FACP, discusses the rapidly evolving treatment landscape in multiple myeloma.

Dr. Lin on Patient Eligibility for CAR T-cell Therapy in Hematologic Caners

August 17th 2022

Yi Lin, MD, PhD, discusses patient eligibility for CAR T-cell therapy in hematologic cancers.

Dr. Florez (Duma) on Nihilism in SCLC

August 17th 2022

Narjust Florez (Duma), MD, discusses nihilism in small cell lung cancer.

Dr. Ahn on Choosing Between Treatment Options in CLL

August 16th 2022

Inhye Ahn, MD, physician, discusses choosing between treatment options in chronic lymphocytic leukemia.

Dr. Bazhenova on the Challenges of Second-Line Therapy in SCLC

August 16th 2022

Lyudmila A. Bazhenova, MD, discusses the challenges of second-line therapy in small cell lung cancer.

Dr Tarantino on Second-line Treatment Selection in HER2+ Metastatic Breast Cancer

August 16th 2022

Paolo Tarantino, MD, researcher, the European Institute of Oncology; clinical research fellow, Dana-Farber Cancer Institute, discusses the options available in the second line for patients with HER2-positive metastatic breast cancer.

Dr. Melosky on the Use of Lurbinectedin in SCLC

August 16th 2022

Barbara Melosky, MD, FRCPC, discusses the use of lurbinectedin in small cell lung cancer.

Dr. Beckermann on the Future of Treatment in RCC

August 16th 2022

Kathryn E. Beckermann, MD, PhD, discusses the future of treatment in renal cell carcinoma.

Dr. Ryan on Objectives for Investigating Ibrutinib Plus Obinutuzumab in R/R CLL

August 16th 2022

Christine Ryan, MD, discusses the objectives for investigating different sequencing options for ibrutinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

Dr. Shah on How to Address CAR T-Cell Therapy Failure in Hematologic Malignancies

August 16th 2022

Nirav N. Shah, MD, discusses treatment options following CAR T-cell therapy failure in hematologic malignancies.

Dr. He on the Future of Durvalumab Plus Chemotherapy in Biliary Tract Cancer

August 12th 2022

Aiwu Ruth He, MD, PhD, discusses next steps for durvalumab in combination with gemcitabine plus cisplatin in patients with advanced biliary tract cancer.

Dr. Katz on Neoadjuvant mFOLFIRINOX in Pancreatic Cancer

August 11th 2022

Matthew H. G. Katz, MD, CMQ, FACS, FASCO, discusses the efficacy of mFOLFIRINOX, a chemotherapy regimen consisting of oxaliplatin, irinotecan, leucovorin, and fluorouracil, prior to pancreatectomy in patients with borderline resectable pancreatic cancer.

Dr. Jonasch on the Future of Belzutifan in Clear Cell RCC

August 11th 2022

Eric Jonasch, MD, discusses the future of belzutifan (Welireg) in clear cell renal cell carcinoma.

Dr. Michot on the Examination of CC-99282 in Relapsed/Refractory NHL

August 11th 2022

Jean-Marie Michot, MD, discusses the examination of CC-99282 in relapsed/refractory non–Hodgkin lymphoma.

Dr. Elamin on Poziotinib Efficacy and Mutation Insertion Location in NSCLC

August 11th 2022

Yasir Y. Elamin, MD, discusses the efficacy of poziotinib in patients with EGFR exon 20–mutated non–small cell lung cancer with near-loop vs far-loop mutations.